Altria account plan
Leading tobacco product manufacturer
At a glance
Altria makes and sells US nicotine products, including Marlboro cigarettes, Copenhagen, on! pouches and NJOY e-vapor; FY2025 net revenues $23,279 million.
Altria Group, Inc., based in Richmond, Virginia, is a holding company whose operating companies make and sell nicotine products almost entirely in the United States: Philip Morris USA (cigarettes, including Marlboro), John Middleton (Black & Mild cigars), U.S. Smokeless Tobacco Company (Copenhagen and Skoal), Helix Innovations (on! nicotine pouches) and NJOY (e-vapor). Products go mainly to wholesalers and large retailers; one customer accounted for about 23% and another for about 19% of 2025 net revenues. In FY2025 net revenues were $23,279 million (-3.1%), reported net earnings $6,947 million and adjusted diluted EPS $5.42. Altria employed about 5,900 people at December 31, 2025 and holds equity stakes in ABI and Cronos.
Business units
Smokeable products
about 88% of FY2025 net revenues ($20,485 million)PM USA cigarettes (Marlboro, Virginia Slims, Parliament, L&M, Basic) and Middleton cigars. Marlboro held 39.5% of the total cigarette category in Q3 2026 while discount share grew; nine-month 2026 adjusted OCI rose 4.1% to $8,766 million at a 64.8% margin.
Oral tobacco products
about 12% of FY2025 net revenues ($2,802 million)USSTC moist smokeless tobacco (Copenhagen, Skoal, Red Seal) and Helix on! nicotine pouches. Shipments fell 5.4% over nine months of 2026 as MST declined while on! grew 7.7%; nine-month adjusted OCI was $1,339 million (-4.0%).
E-vapor products (NJOY)
NJOY ACE and NJOY Daily; NJOY ACE remains under an ITC exclusion order from JUUL patent litigation, and Altria recorded $2,128 million of e-vapor impairments in 2025. Since 2026 it sits in the all other category; Altria says it plans to re-enter the e-vapor market.
All other
Horizon Innovations (75%-owned heated tobacco JV with Japan Tobacco, awaiting FDA authorisation of Ploom), Helix International (on! outside the US) and R&D on new product platforms.
Strategic priorities
- 2028 Enterprise Goals
- Mid-single digits adjusted diluted EPS CAGR from a $4.87 base in 2022, progressive dividend growth in mid-single digits through 2028, debt-to-Consolidated EBITDA of about 2.0x and total adjusted OCI margin of at least 60% each year.
- Grow on! in nicotine pouches
- Pouches reached 61.2% of the oral category in Q3 2026; on! PLUS 12 mg went national with new flavours, backed by a retail trade program in stores representing approximately 90% of its volume.
- Defend Marlboro's premium position
- A data-driven, total portfolio approach uses Marlboro Cowboy Cut for value-sensitive smokers and Basic in discount; Marlboro held 60.0% of premium in Q3 2026.
- Optimize & Accelerate
- Centralising work, outsourcing transactional activities and automating processes for cumulative savings of at least $600 million by end-2029, reinvested in the business.
- Growth beyond the US and beyond nicotine
- Compete in top international innovative oral markets, develop heated tobacco and e-vapor abroad, and broadly distribute at least five non-nicotine products by 2028.
Latest results
In Q3 2026 net revenues rose 1.0% to $6,132 million and adjusted diluted EPS 4.8% to $1.52. Over nine months net revenues were $17,671 million (+1.4%) and adjusted diluted EPS $4.33 (+5.1%), with higher pricing and duty refunds on contract-manufactured export cigarettes offsetting lower volume and mix toward discount. Domestic cigarette volume fell 2.8% over nine months. Full-year 2026 adjusted diluted EPS guidance was raised to $5.66 to $5.74, growth of 4.5% to 6.0% from $5.42 in 2025.
Investments and deals
- USSTC Facilities Consolidation
- Announced May 2026: Nashville, Tennessee manufacturing moves to a new plant on the Hopkinsville, Kentucky campus, substantially complete in Q1 2028, for about $180 million of pre-tax charges.
- Capital expenditure
- 2025 capex rose 52.1% to $216 million for manufacturing capabilities and innovative products; 2026 capex is expected at $300 million to $375 million.
- Contract manufacturing
- Contract-manufactured export cigarettes reached 2,941 million sticks over nine months of 2026 versus 786 million; 2026 guidance includes investments in contract manufacturing capabilities.
- Shareholder returns
- Dividend raised 4.7% to $1.11 per quarter in August 2026; buybacks of $735 million over nine months and a $1 billion program expansion expiring December 31, 2027.
Challenges and risks
- Cigarette volume decline and trade-down
- Inflation-squeezed adult consumers move to discount; industry discount share reached 34.1% in Q3 2026 and Marlboro's total share fell 1.0 point.
- Illicit e-vapor
- Illicit flavored disposables are estimated at about 70% of the e-vapor category, and Altria says enforcement is insufficient.
- NJOY patent litigation
- The ITC exclusion order keeps NJOY ACE off the market, and guidance assumes it does not return in 2026.
- MST decline and pouch competition
- Copenhagen and Skoal shipments fell 10.5% and 12.5% over nine months of 2026, while competitive investment in pouches remained elevated.
- FDA regulation
- PMTA outcomes, a proposed maximum-nicotine standard and state flavour bans weigh on the portfolio; Helix and NJOY sued the FDA over authorization timelines.
What leadership says
“Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future.”
“Sustained progress on harm reduction requires a more durable foundation, an efficient and predictable authorization process established through rulemaking.”
“We have not announced when we're going back in the market, but we do plan on being back in the evapor market”
“For harm reduction to succeed, 2 things are necessary, a more efficient authorization process and consistent enforcement over time.”
Where a supplier can help
- Process automation and outsourcing
- Optimize & Accelerate's outsourcing of transactional activities and automation, with at least $600 million of targeted savings, opens doors for automation and business-process service providers.
- Manufacturing and plant build-out
- The USSTC move to Hopkinsville and higher 2026 capex for manufacturing and contract manufacturing favour equipment, engineering and construction suppliers.
- Retail execution and trade marketing
- Growing on! PLUS through retail trade programs, events and paid social, and the data-driven Marlboro portfolio approach, call for retail analytics and trade marketing tools.
- Regulatory and compliance support
- PMTA filings, FDA rulemaking and planned e-vapor re-entry create demand for regulatory science, testing and compliance services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Altria?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Altria Group Form 10-K for fiscal year 2025
- Altria Group is a US-only nicotine holding company: PM USA (Marlboro cigarettes), John Middleton (Black & Mild cigars), USSTC (Copenhagen, Skoal MST), Helix (on! oral nicotine pouches) and NJOY (e-vapor), plus the Horizon heated-tobacco JV (75% Altria, 25% Japan Tobacco) and equity stakes in ABI and Cronos. About 5,900 employees at December 31, 2025.
- FY2025 net revenues were $23,279 million (down 3.1%); revenues net of excise taxes $20,139 million. Reported diluted EPS fell 37% to $4.12 (2024 included a $2.7 billion gain on the IQOS rights sale); adjusted diluted EPS rose 4.4% to $5.42.
- Smokeable products remain the profit engine: $20,485 million net revenues and $11,064 million adjusted OCI (63.4% margin), despite cigarette shipments falling 10.0% to 61.8 billion units; pricing more than offset volume.
- Oral tobacco products: $2,802 million net revenues, $1,835 million adjusted OCI (67.9% margin); retail share fell 5.4 points to 31.9% as nicotine pouches reached 53.3% of the US oral category and on!'s share of pouches fell to 15.4%.
- E-vapor (NJOY) lost $2,297 million of reported OCI, driven by $2,128 million of goodwill and intangible impairments: NJOY ACE is banned by an ITC exclusion order and illicit flavored disposables are about 70% of the e-vapor category. Smoke-free 2028 goals are being reassessed.
- 2028 Enterprise Goals: mid-single-digit adjusted EPS CAGR from a $4.87 2022 base (3.6% achieved through 2025), mid-single-digit dividend growth, debt/EBITDA of about 2.0x, adjusted OCI margin of at least 60%, and at least five non-nicotine products by 2028.
- Optimize & Accelerate initiative (centralisation, outsourcing, automation): cumulative savings of at least $600 million by end-2029, about $175 million of charges; capex rose 52.1% to $216 million in 2025 and is guided at $300-375 million for 2026.
- Cash returns: dividends of about $6,960 million in 2025, $1.0 billion buyback expansion; debt $25.7 billion, debt/Consolidated EBITDA 2.0.
- Leadership change: CEO William F. Gifford, Jr. retires at the May 14, 2026 annual meeting; CFO Salvatore Mancuso becomes CEO and Heather A. Newman becomes CFO.
- Altria Group Form 10-Q for the third quarter of 2026
- Form 10-Q for Q3 2026: nine-month net revenues rose 1.4% to $17,671 million (Q3: $6,132 million, +1.0%); reported diluted EPS $4.18 (+21.2%, lapping the 2025 e-vapor goodwill impairment), adjusted diluted EPS $4.33 (+5.1%).
- Segments are now two: smokeable products and oral tobacco products. NJOY e-vapor moved into "all other" with Horizon, Helix International and R&D.
- Smokeable: adjusted OCI $8,766 million (+4.1%), margin 64.8%; domestic cigarette shipments -2.8% to 45,146 million sticks while discount (Basic, L&M) rose 69.7%; contract-manufactured export cigarettes jumped to 2,941 million sticks from 786 million.
- Refunds of taxes and duties paid on imported cigarettes added $182 million to smokeable OCI over nine months and cut excise taxes 10.8%.
- Oral: adjusted OCI $1,339 million (-4.0%), margin 66.8%; shipments -5.4% as Copenhagen (-10.5%) and Skoal (-12.5%) fell and on! grew 7.7% to 143.9 million cans; retail share 28.6% (-3.9 points); pouches reached 61.2% of the oral category in Q3.
- USSTC will move its Nashville manufacturing to a new facility in Hopkinsville, Kentucky by Q1 2028, with about $180 million of pre-tax charges ($87 million so far).
- FDA issued more on! MGOs in August 2026 (autumn spice, rich berry, cappuccino; 2 mg and 4 mg); NJOY ACE stays under the ITC ban; Horizon still has no product in market.
- Balance sheet: cash $2.7 billion, long-term debt $24.1 billion, debt/Consolidated EBITDA 1.9; quarterly dividend raised 4.7% to $1.11 ($4.44 annualised).
- Altria reports 2026 third-quarter and nine-months results (earnings release)
- Q3 2026 earnings release (October 29, 2026): adjusted diluted EPS +4.8% to $1.52 and reported diluted EPS +7.1% to $1.51; nine-month adjusted diluted EPS +5.1% to $4.33.
- Net revenues rose 1.0% to $6,132 million in Q3; revenues net of excise taxes rose 3.6% to $5,441 million.
- 2026 guidance raised: adjusted diluted EPS of $5.66 to $5.74, growth of 4.5% to 6.0% from $5.42 in 2025. The guidance assumes NJOY ACE does not return to market in 2026.
- Smokeable products adjusted OCI +3.9% in Q3 (margin 64.5%), on higher pricing and refunds of duties on imported cigarettes; Marlboro held 60.0% of the premium segment.
- Oral tobacco adjusted OCI -3.7% in Q3 (margin 66.4%) as on! PLUS investment and MST declines weighed.
- Helix added Blueberry Mint and Mango Pineapple to on! PLUS across 6, 9 and 12 mg; Watermelon Mint follows in Q4 in select stores.
- Cash returns: 5.9 million shares bought back in Q3 for $400 million; a further $1 billion buyback expansion runs to December 31, 2027; the August dividend increase was the 61st in 57 years ($4.44 annualised).
- CEO Sal Mancuso credits PM USA's "data-driven, total portfolio approach", with Cowboy Cut strengthening Marlboro and Basic gaining in discount.
- Altria Q3 2026 earnings call transcript
- Q3 2026 call (October 29, 2026), CEO Sal Mancuso and CFO Heather Newman. Guidance was raised from an initial 2.5% to 5% to 4.5% to 6% adjusted EPS growth after a strong nine months.
- on!: Q3 shipments +13.3% to 47.8 million cans, retail share 8.3%; on! PLUS 12 mg went national, new flavours (Blueberry Mint, Mango Pineapple, Watermelon Mint in November) and a retail trade program securing premium positioning in stores with about 90% of its volume.
- Regulation: Helix and NJOY sued the FDA to force reviews within the 180-day statutory timeframe; the FDA then announced it would pursue new PMTA rulemaking, which Altria welcomes.
- Illicit vapes: enforcement is having an effect; Altria estimates about 20 million adult vapers, down 1 million year on year. NJOY ACE has been redesigned around the patents and Altria plans to return to e-vapor in a "disciplined" way.
- Smokeable: price realization 4.4%; Marlboro Cowboy Cut is in about 100,000 stores (about 75% of cigarette volume) and Marlboro reached about 60% of premium.
- Duty drawback on cigarette exports is building; the PMI contract manufacturing agreement starts in 2027. Altria declined to size the 2027 benefit.
- ABI adjusted equity earnings $191 million (+21.7%); over $6 billion returned to shareholders in nine months; debt/EBITDA 1.9x.
- Altria Q2 2026 earnings call transcript
- Q2 2026 call (July 30, 2026): Sal Mancuso's first quarter as CEO, Heather Newman introduced as the new CFO. H1 adjusted diluted EPS +4.9% to $2.80; nearly $3.9 billion returned to shareholders in the first half.
- on! PLUS went national in about 120,000 stores (covering about 90% of nicotine product volume, per Mancuso); on! retail share rose to 8.6% in Q2 and Altria credits the NICOSILK soft pouch. Q2 on! shipments fell 4.2% on trade inventory.
- Regulatory: the FDA's updated enforcement priorities are "a positive step"; the on! PLUS authorisations open a faster supplemental PMTA path for line extensions. NJOY ACE was modified so it no longer infringes the four patents, and a supplemental PMTA was submitted.
- Illicit vapes: federal seizures above $250 million in the quarter; about 20 million adult vapers, flat year on year.
- Smokeable adjusted OCI +2.4% to $3 billion in Q2, margin 64.8%; Marlboro Cowboy Cut launched for value-seeking premium smokers; Basic supported in about 35,000 stores; premium is about 85% of cigarette category profit.
- Guidance narrowed to $5.61-$5.72 adjusted EPS (+3.5% to 5.5%); about $1 billion of excess cash a year after the dividend goes to debt, buybacks or M&A.
Questions about Altria
What does Altria do?
Altria's operating companies make and sell nicotine products in the United States: Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, on! nicotine pouches and NJOY e-vapor.
What is Altria's revenue?
FY2025 net revenues were $23,279 million, down 3.1%. Over the first nine months of 2026 net revenues were $17,671 million, up 1.4%.
How many employees does Altria have?
About 5,900 people at December 31, 2025, 26% of them hourly unionised manufacturing employees.
Who leads Altria?
Sal Mancuso became CEO after the May 14, 2026 annual meeting, succeeding William F. Gifford, Jr.; Heather Newman is CFO.
What is Altria's strategy?
Its Vision, Moving Beyond Smoking, aims to transition adult smokers to smoke-free products such as on! and NJOY while keeping leadership in US tobacco and meeting its 2028 Enterprise Goals.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)